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aneurysm-related risk after open repair is greatly reduced
but persists with the potential for subsequent anastomotic
or true aneurysmal degeneration. Endovascular aneurysm
repair with endoluminal placement of a stent graft provides
a less invasive alternative to standard open surgery with
reduced morbidity and more rapid patient recovery.3-7
However, the long-term effectiveness of this approach com-
pared with that of open surgery or with observation and no
treatment is not well defined. This report will review the
current clinical results of abdominal aortic aneurysm treat-
ment with the AneuRx stent graft and consider issues
related to its effectiveness against open surgery and the
natural history of abdominal aortic aneurysms. We will
also provide a current perspective on the worldwide use of
the AneuRx stent graft for the treatment of patients with
abdominal aortic aneurysms.
DEVELOPMENT OF THE ANEURX STENT
GRAFT
The AneuRx stent graft was designed and engineered
by Dr. Thomas J. Fogarty and Fogarty Engineering in
1993.8-10 The device and delivery system were perfected
by AneuRx, Inc (Sunnyvale, Calif), and animal experi-
The primary objective in treating patients with aortic
aneurysms is to prevent aneurysm rupture and death from
aneurysm rupture. The effectiveness of any treatment of
abdominal aortic aneurysms must be balanced against the
risk of the treatment itself and the risk of no treatment,
that is, the natural history of the aneurysm to rupture.
Open repair with direct exposure of the aneurysm and
transmural suture fixation of a prosthetic graft is generally
effective in preventing aortic aneurysm rupture but
requires major abdominal surgery and is associated with
significant morbidity and mortality.1,2 The long-term
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Objective: The objective was to review the current results of endovascular abdominal aortic aneurysm repair with the
AneuRx stent graft and to determine the effectiveness of the device in achieving the primary objective of preventing
aneurysm rupture.
Methods: The outcome of all patients treated during the past 4 years in the U.S. AneuRx clinical trial was determined,
and the worldwide clinical experience was reviewed.
Results: A total of 1192 patients were treated with the AneuRx stent graft during all phases of the U.S. Clinical Trial
from June 1996 to November 1999, with follow-up extending to June 2000. Ten (0.8%) patients have had aneurysm
rupture, with most ruptures (n = 6) occurring in 174 (3.4%) patients treated with an early stiff bifurcation stent graft
design used in phase I and in the initial stages of phase II. Since the current, flexible, segmented bifurcation stent graft
design was introduced, four (0.4%) ruptures have occurred among 1018 patients treated. Of these, one was during
implantation, two were placed too far below the renal arteries, and one patient refused treatment of a type I endoleak.
Kaplan-Meier analysis of all 1192 patients treated with the AneuRx stent graft including both stent graft designs revealed
the patient survival rate to be 93% at 1 year, 88% at 2 years, and 86% at 3 years, freedom from conversion to open repair
to be 98% at 1 year, 97% at 2 years, and 93% at 3 years, and freedom from secondary procedure to be 94% at 1 year, 92%
at 2 years, and 88% at 3 years. Freedom from aneurysm rupture with the commercially available segmented bifurcation
stent graft was 99.7% at 1 year, 99.5% at 2 years, and 99.5% at 3 years. The presence or absence of endoleak on contrast
computed tomography scanning after stent graft placement was not found to be a significant predictor of long-term out-
come measures. Worldwide experience with the AneuRx device now approaches 10,000 patients.
Conclusions: Endovascular management of abdominal aortic aneurysms with the AneuRx stent graft has markedly reduced
the risk of aneurysm rupture while eliminating the need for open aneurysm surgery in 98% of patients at 1 year and 93%
of patients at 3 years. The device was effective in preventing aneurysm rupture in 99.5% of patients over a 3-year period.
The overall patient survival rate was 93% at 1 year and 86% at 3 years. (J Vasc Surg 2001;33:S135-45.)
ments were concluded at Stanford University and Harbor
UCLA in 1995.12 European CE mark was granted in
March 1997. U.S. clinical trials, in accord with Food and
Drug Administration (FDA) guidelines, were begun in
1996. The first AneuRx device implanted in the United
States was by Dr. Rodney White at Harbor UCLA on
June 3, 1996. The first AneuRx device in Europe was
implanted by Dr. Frans Moll in the Netherlands in
September 1996. AneuRx, Inc. was acquired by
Medtronic, Inc (Minneapolis, Minn) in 1996 and is now
operating as a part of Medtronic AVE (Santa Rosa, Calif).
The U.S. phase II clinical trial comparing the AneuRx
stent graft with standard open surgical aneurysm repair
began in April 1997 and was carried out at 13 clinical sites
throughout the United States. The 1-year results were
reviewed on June 23, 1999, by the FDA Advisory Panel,
which recommended approval. The FDA granted market
approval for the AneuRx device on September 28, 1999.
THE ANEURX STENT GRAFT SYSTEM
The AneuRx stent graft is a modular, bifurcated
endovascular device designed to treat infrarenal aortic
aneurysms. Each stent graft module consists of a thin-
walled, noncrimped, woven polyester graft that is joined
to a nickel-titanium (Nitinol) exoskeleton by numerous
individual polyester sutures (more than 2000 suture con-
nections in the bifurcation module). The self-expanding
Nitinol stent rings provide both radial and columnar
structural support throughout the length of the graft, and
the polyester graft provides a smooth, impervious blood
flow conduit. Each individual stent graft module is loaded
inside a delivery catheter, which is introduced over a stiff
0.035-inch guidewire and positioned with x-ray fluoro-
scopic control.
The primary aortic bifurcation module is contained in a
21F (OD) delivery catheter, and the iliac modules are con-
tained in 16F delivery catheters. A nosecone orientation
marker and radio-opaque markers on the stent graft allow
radial and longitudinal orientation of the stent graft under
fluoroscopic guidance. The self-expanding stent graft is
deployed by retraction of the delivery catheter-covering
sheath with a deployment handle. A new tapered nosecone
and new integrated deployment-delivery system is being
introduced and will eventually replace the two-component
delivery system.
In April 1998, early in the AneuRx clinical trial, the
FDA approved a manufacturing change of the bifurcation
stent graft module. The initial bifurcation stent graft mod-
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Fig 1. AneuRx stent graft composed of Nitinol exoskeleton joined to woven polyester graft with multiple polyester sutures. A, Original
bifurcation module included single 5-cm long, unbending bifurcation stent. B, Currently available device is constructed with individual
1 cm long stent rings throughout its length and provides flexibility throughout length of stent graft.
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ules were manufactured with a single-unit Nitinol bifurca-
tion stent, 5 cm in length, coupled proximally and distally
to individual 1 cm long Nitinol rings joined together end
to end (Fig l, A). After April 1998, the entire length of the
bifurcation stent body was constructed with individual 1
cm long Nitinol rings joined together end to end (Fig l,
B). The segmented body construction resulted in flexibil-
ity of the bifurcated graft throughout the length of the
stent graft and eliminated the stiff, unbending 5 cm long
proximal bifurcation segment (Fig 2). The commercially
available AneuRx stent graft has the segmented body con-
struction.
U. S. MULTICENTER CLINICAL TRIAL
The AneuRx Stent Graft System was evaluated under
the FDA Investigational Device Exemption (IDE)
Application Number G960016 for Endovascular Stent
Graft and Delivery Catheter. The study was designed in
three phases. Phase I began in June 1996 and was
designed as a feasibility study involving 40 patients at four
study sites. Only one follow-up year was required, but
most patients in this phase continue to be monitored.
Phase II began in April 1997 and was a prospective, non-
randomized, controlled clinical investigation comparing
endovascular repair using the AneuRx stent graft with
standard open surgical repair. Phase II included 13 study
sites and included a 1-year follow up, which has been
extended to 5 years for the patients receiving stent grafts.
Phase III began in August 1998 and included additional
patients with stent grafts treated at a total of 19 clinical
sites (13 phase II sites and 6 new sites). These patients will
be monitored for 5 years. The clinical study sites are listed
in the Appendix.
The numbers of patients treated in the clinical trial as
of June 3, 2000, are as follows: phase I - 40 patients, phase
II stent graft - 424 patients, phase II surgical control - 66
patients, and phase III stent graft - 641 patients. In addi-
tion, 87 patients during phases II and III were treated
with the AneuRx stent graft on a compassionate use/high-
risk basis. The total number of patients treated with the
AneuRx stent graft during all phases of the clinical trial
was 1192.
Fig 2. Curved planar reformation of spiral CT angiograms of tortuous abdominal aortic aneurysms treated with AneuRx stent graft (A).
Stiff bifurcation stent graft module used in 174 patients in clinical trial. Arrows denote stiff bifurcation segment (B). Segmented bifur-
cation stent graft was used in 1018 patients in clinical trial and is currently FDA-approved for clinical use. Arrows define flexible bifur-
cation segment.
A B
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Patient selection. Patients with nonruptured infrarenal
aortic and aortoiliac aneurysms were candidates for the trial
if the aneurysm met one of the following criteria: larger
than 5 cm in diameter, between 4 and 5 cm in diameter
with a documented increase in diameter of 0.5 cm in the
past 6 months, twice the diameter of the infrarenal neck, or
saccular. Additional requirements included an infrarenal
neck between 18 and 26 mm in diameter with a length
below the most inferior renal artery of at least 1 cm.
Patient exclusions included ruptured or leaking aneurysms
and suprarenal, thoracic, and inflammatory aneurysms.
Patient selection criteria in the clinical trial were the same
for patients in both the stent graft and surgical control
groups. Patients were evaluated with preoperative and
postoperative computed tomography (CT) scans and
Duplex ultrasound scanning and were monitored at inter-
vals of 1 month, 6 months, and 12 months and annually
thereafter with clinical evaluation, plain abdominal x-ray
evaluation, and CT scans.
Data at each study site are managed by a study coor-
dinator and externally audited with interval site visits. Data
are entered into a central database. A data safety and mon-
Fig 3. Freedom from aneurysm rupture. Kaplan-Meier analysis.
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itoring board reviews adverse event information. Imaging
data from patients in phase II of the study (CT scans and
abdominal x-ray evaluations) are independently evaluated
by a Radiologic Core Laboratory with expertise in radio-
logic imaging and with no affiliation to any of the study
sites or investigators. Statistical analysis of the data is over-
seen by D.A.B. of the Stanford University Medical Center,
Department of Health Research and Policy.
Early results. The initial experience of 190 patients
treated with the AneuRx stent graft (patients in both
phase I and phase II) was compared with that of 60
patients in a surgical control group with 1-year follow-up
and was presented to the International Society for
Cardiovascular Surgery in June 1998 and published in
1999.4 There were no significant differences in preoper-
ative risk factors of comorbidities between the patients in
the surgical control and stent graft groups. Stent graft
deployment was successful in 97% of patients. There was
no difference in operative mortality between the groups
(0% in the surgery group and 1% in the stent graft
group). Patients who underwent stent graft repair had
60% less blood loss compared with patients who under-
went open surgery (P < .001), and these patients
required 80% less blood transfusion (P < .05). There was
a marked reduction in the time to extubation, discharge
from the intensive care unit, ambulation without assis-
tance, and eating a regular diet in the stent graft group
compared with the surgery group. Major morbidity was
reduced by 50% in the stent graft group (P < .05), and
hospital length of stay was reduced from 9.3 to 3.4 days
(P < .001).4
Phase II clinical trial. The phase II controlled trial of
416 patients in the stent graft group compared with 66
patients undergoing open aneurysm repair was presented
to the FDA Advisory Panel on June 23, 1999. The results
did not differ significantly from the previously published
results and demonstrated the following. Successful graft
deployment was achieved in 98% of patients, and the sur-
gical conversion rate was 1.5%; there was no difference in
the 30-day mortality rate between patients in the stent
graft group (2%) and those in the surgical group (0%).
There was a 50% reduction in major morbidity compared
with open repair, a 66% reduction in blood loss, and a 63%
reduction in hospital length of stay. Patients recovered
Fig 4. Survival after endovascular aneurysm repair. Kaplan-Meier analysis.
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more quickly and had earlier return to function compared
with patients undergoing open surgery. The physician-
reported endoleak rate at the time of hospital discharge
was 38%, which was reduced to 13% at 1 month, 16% at 6
months, and 11% at 12 months. Two (0.5%) patients had
aneurysm rupture, one during the implantation procedure
and one 14 months after implantation of a stiff bifurcation
stent graft. These ruptures are included in the later analy-
sis in this article. Five percent of patients required a sec-
ondary endovascular procedure for endoleak, and 2%
required a secondary procedure for nonpatency of the
stent graft. The primary graft patency rate was 98%, and
the secondary graft patency rate was 99%.
FOUR-YEAR RESULTS OF U.S. ANEURX
CLINICAL TRIAL
All patients entered into the endovascular treatment
arm beginning with the first patient in phase I (June 3,
1996) and ending with the last patient treated in phase III
on November 4, 1999, were reviewed. The follow-up
period extended for 4 years through June 3, 2000, with a
mean of 73.4 + 8.0 SD months. All patients were included
in this analysis, with no patient exclusions for the initial
learning curve, device manufacturing changes, compas-
sionate use, or other reasons.
A total of 1192 patients were reviewed to determine
long-term outcome on intent-to-treat basis. Patients
included 1058 (89%) men and 134 (11%) women with a
mean age of 73.4 ± 8.0 SD years (range 45 to 96 years).
Patients had multiple risk factors and comorbidities, and 92%
of patients had American Society of Anesthesiologists (ASA)
risk classification of III or IV. The mean preoperative
aneurysm diameter was 5.6 + 0.3 SD cm. The mean
aneurysm neck length was 27.3 + 12.2 SD mm, and the
mean neck diameter was 22.3 + 2.9 SD mm. The primary
end points for analysis included aneurysm rupture, death
from aneurysm rupture, death from any cause, surgical con-
version, and secondary procedures for endoleak/migration
or graft nonpatency.
Aneurysm rupture. The first report of aneurysm rup-
ture after successful AneuRx stent graft repair was in
1999.4 This was a patient in phase I with a 5.5-cm
Fig 5. Freedom from surgical conversion. Kaplan-Meier analysis.
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aneurysm and a short angulated neck who had a rupture
23 months after endovascular repair. The main bifurcation
module used in this patient was the early stiff body design,
which is no longer manufactured. Since that time there
have been seven additional cases of aneurysm rupture after
successful AneuRx stent graft repair. Three of these
patients were reported by Politz et al13 in the March 2000
issue of the Journal of Vascular Surgery. Seven of the eight
patients who had rupture including the three reported by
Politz et al and two additional patients who had aneurysm
rupture during the implantation procedure were reported
by Zarins et al14 in the May 2000 issue of the Journal of
Vascular Surgery. Thus as of June 3, 2000, 4 years since
the first device implantation, there have been a total of 10
aneurysm ruptures (two during the implant procedure,
eight after implantation) among the 1192 (0.8%) patients
entered into the endovascular treatment arm of the U.S.
AneuRx Clinical Trial.
Two of the ruptures occurred during the treatment
period, and both underwent successful surgical conver-
sion. One was related to intraoperative balloon dilation of
the proximal aortic neck in an attempt to seal a type I
endoleak, and the other was related to instrumentation
and perforation of the aneurysm sac. The eight ruptures
after successful endovascular repair occurred 3 weeks to 26
months (mean 17 months) after endovascular repair. Five
patients survived open surgical repair, two died in the peri-
operativc period, and one died after refusing operation
(rupture-related mortality: 0.3%).
Before rupture occurred, two patients had type I iliac
endoleaks and aneurysm enlargement and refused recom-
mended treatment with iliac extender modules. Six patients
had no documented endoleak and no aneurysm enlarge-
ment. Four ruptured as a result of proximal fixation failure
in angulated necks, and two ruptured as a result of
aneurysm tortuosity and separation of the iliac limb from
Fig 6. Freedom from secondary procedure. Kaplan Meier analysis.
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the junction gate. Retrospective analysis of all patients with
aneurysm rupture after successful stent graft repair revealed
evidence of insecure fixation either proximally, distally, or
at the junction gate, which could have been treated with
stent graft extender modules before rupture.14
Single-unit versus segmented bifurcation stent
body. All 40 patients in phase I were treated with the orig-
inal, single-unit, stiff bifurcation body, as were 134 patients
in the beginning of the phase II clinical trail. Subsequently,
all patients treated with the AneuRx stent graft have
received flexible, segmented bifurcation stent grafts. Thus
174 (15%) patients were treated with the stiff body stent
graft, whereas 1018 (85%) patients were treated with the
flexible stent graft. Among the 10 patients with rupture, six
had received the stiff body stent graft, and four had
received the flexible stent graft. Thus the risk of aneurysm
rupture with the stiff body stent graft was much higher (6
of 174, 3.4%) than with the flexible body stent graft (4 of
1018, 0.4%). Kaplan-Meier analysis revealed a significant
reduction in the risk of aneurysm rupture among patients
receiving the flexible, segmented stent graft compared with
those treated with the stiff body stent graft (P < .002,
Mantel-Haenszel test, Fig 3). Freedom from aneurysm
rupture with the flexible, segmented stent graft was 99.7%
at 1 year, 99.5% at 2 years, and 99.5% at 3 years (Fig 3).
One of the two patients with periprocedural rupture
received a stiff device, whereas the other received a flexible
device. Among the eight patients with rupture after suc-
cessful repair, five received the stiff body graft and three
received the flexible graft. Two of the five stiff devices had
been placed in aneurysms with short, angulated necks with
ultimate loss of proximal fixation, and two experienced
progressive anterior angulation of the stent graft over time,
resulting in separation of the iliac limb from the junction
gate. It is likely that the inability of the stiff bifurcation
module to flex in tortuous or shrinking aneurysms exacer-
bated the angulation forces at either the proximal or distal
end of the rigid 5 cm long segment, resulting in ultimate
fixation failure. The fifth patient had a type I iliac endoleak
and refused treatment. Among the three patients with flex-
ible stent grafts who had rupture, two had severely angu-
lated necks with initial positioning of the device low in the
neck, well below the renal arteries. The third patient had a
type I iliac endoleak and refused treatment.
Survival. Among the 1192 patients, a total of 119
(10%) patients have died during the 4-year time course of
study. The 30-day mortality rate was 2% (23 of 1192).
Four (0.3%) patients died of aneurysm rupture after suc-
cessful endovascular repair, three after emergent opera-
tion, and one refused operation. One patient died of
aneurysm rupture before treatment and one of a ruptured
arch aneurysm after treatment. The remaining patients
died of nonaneurysm causes. The causes of death were
cardiac in 49, cancer in 20, pulmonary in 19, renal in 7,
gastrointestinal in 4, sepsis and multisystem organ failure
in 5, stroke in 3, pulmonary embolism in 1, and mesen-
teric thrombosis in 1. The cause of death for four patients
has not been determined. Kaplan-Meier survival analysis
(Fig 4) reveals a 1-year survival rate of 93%, a 2-year sur-
vival rate of 88%, and a 3-year survival of 86%.
Secondary procedures. A total of 33 (2.8%) patients
have undergone conversion to open surgical repair includ-
ing the nine patients who underwent open repair for
aneurysm rupture. There were 15 (1.3%) surgical conver-
sions within the first 30 days and 18 (1.5%) late surgical
conversions at an average time of 22 months after endovas-
cular repair. The Kaplan-Meier estimate of freedom from
surgical conversion is 98% at 1 year, 97% at 2 years, and
93% at 3 years (Fig 5). A total of 107 secondary procedures
have been performed in 94 (8%) patients; 82 patients had
one procedure, 11 patients had two procedures, and one
patient had more than two procedures. Freedom from sec-
ondary procedure (Kaplan-Meier estimate) was 94% at 1
year, 92% at 2 years, and 88% at 3 years (Fig 6).
ENDOLEAKS
Evidence of blood flow in the aneurysm sac
(endoleak) is commonly seen in patients after endovascu-
lar aneurysm repair. Although some have considered this
to be evidence of an unsuccessful aneurysm repair,15-18 the
true significance of this finding remains unclear.19,20 To
determine whether evidence of blood flow in the
aneurysm sac (endoleak) was a meaningful predictor of
clinical outcome after successful endovascular aneurysm
repair, we reviewed all patients in phase II of the AneuRx
Multicenter Clinical Trial with successful stent graft
implantation and predischarge contrast CT imaging. The
clinical outcome of patients with evidence of endoleak was
compared with that of patients without evidence of
endoleak. The results were presented at the Western
Vascular Society Meeting in Lake Tahoe in September
1999 and were published in the July 2000 issue of the
Journal of Vascular Surgery.21
The determination of whether an endoleak was pres-
ent after endovascular repair was independently deter-
mined by (1) the 13 clinical centers before hospital
discharge, at 1 month, 6 months, 12 months, and 24
months, and (2) a Radiologic Core Laboratory that inde-
pendently reviewed the contrast CTs at predischarge, 6
months, 12 months, and 24 months. The Centers
reported endoleaks in 152 (38%) of 398 patients on pre-
discharge CT, whereas the Core Lab reported endoleaks
in 50% of these patients (P < .001). Follow-up extended
to 2 years (mean 10 ± 4 months). There were no differ-
ences between patients with and patients without
endoleak before discharge in the following outcome mea-
sures: patient survival, aneurysm rupture, surgical conver-
sion, need for a secondary procedure, aneurysm
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enlargement more than 5 mm, and appearance of a new
endoleak or stent graft migration. Despite a higher
endoleak rate reported by the Core Lab, neither Core
Lab-defined endoleaks nor Center-defined endoleaks at
discharge were significantly related to subsequent out-
come measures. The outcome of patients with type I or
type II endoleaks before discharge was no different from
that of patients with no endoleak.21
At 1 month the endoleak rate had decreased to 13%.
Although patients with persisting endoleaks were more
likely to have aneurysm enlargement at 1 year, there was
no difference in patient survival, aneurysm rupture rate,
surgical conversion, new endoleak, or stent graft migra-
tion between patients with and those without endoleak at
1 month. Kaplan-Meier survival of all patients undergoing
endovascular aneurysm repair was 96% at 1 year and was
independent of endoleak status.21
Thus the presence or absence of endoleak on CT scan
after AneuRx stent graft aneurysm repair does not appear
to predict long-term outcome. Although the identification
of blood flow in the aneurysm sac after endovascular repair
is a meaningful finding, the usefulness of endoleak as a pri-
mary indicator of procedural success or failure remains
unproved. Thus all patients who have undergone endovas-
cular aneurysm repair should be carefully monitored
regardless of endoleak status.
WORLDWIDE EXPERIENCE
Since the initiation of clinical trials in the United
States and the introduction of the device in Europe in
1996, use of the AneuRx stent graft has increased on an
annual basis. The worldwide experience of endovascular
abdominal aortic aneurysm repair with the AneuRx stent
graft now approaches 10,000 patients. A total of 1192
patients were included in the U.S. clinical trial and are
undergoing monitored 5-year follow-up. During the past
8 months, since FDA market approval, 895 physicians
have been trained to implant the device in the United
States, and 370 hospitals have begun using the AneuRx
stent graft. A total of 6700 stent grafts have been shipped
for implantation in the United States. In Europe, the
Middle East, and Australia, more than 2500 patients have
been treated. There have been eight aneurysm ruptures in
the United States and one aneurysm rupture in Europe
after successful implantation, plus two implantation proce-
dure-related ruptures. Six of these 11 ruptures were with
the early prototype stiff body bifurcation stent design dur-
ing the U.S. clinical trial. Therefore as of June 2000 the
worldwide reported aneurysm rupture rate after endovas-
cular repair with the commercially available AneuRx stent
graft is 5 (0.06%) among more than 9000 patients treated
thus far.
As of December 1999 a total of 386 patients treated
with the AneuRx graft have been entered in the Eurostar
Registry from 35 European and Middle East Centers.
Follow-up evaluation has been carried out on 124 patients
at 12 months and 30 patients at 24 months. Patient sur-
vival at 12 months is 87% (Kaplan Meier estimate) and at
24 months is 83% (Kaplan Meier estimate). In the U.K.
experience there has been one reported aneurysm rupture
after AneuRx stent graft repair with successful surgical
conversion.
RUPTURE RISK OF UNTREATED
ANEURYSMS
The risk of aneurysm rupture of untreated aneurysms
is a continuous function of aneurysm size. The annual
rupture rate is near zero for aneurysms less than 4 cm. The
risk is approximately 1% per year for aneurysms 4 to 4.9
cm in diameter, 11% per year for aneurysms 5 to 5.9 cm,
and 25% per year or more for aneurysms greater than 6
cm.22-24 The mean diameter for aneurysms treated in the
AneuRx clinical trial was 5.6 ± 0.3 cm. Thus the 1-year
risk of aneurysm rupture was reduced by more than 98%
compared with the expected risk of rupture of untreated
aneurysms.
Although the risk of aneurysm rupture after endovas-
cular aneurysm repair is very low and markedly reduced
compared with the likelihood of rupture of untreated
aneurysms,24 the possibility of rupture persists even in
patients with no endoleak after the procedure.25,26 The
cause of rupture with the AneuRx stent graft can be traced
to poor proximal, distal, or junctional fixation of the stent
graft, with a higher risk of rupture in patients who were
treated with the early stiff body prototype stent graft and
who had significant aneurysm or neck angulation.
Therefore all patients treated with endovascular aneurysm
repair should continue to be monitored after the proce-
dure with follow-up clinical evaluation and imaging stud-
ies. Patients with evidence of insecure stent graft fixation
or evidence of aneurysm enlargement should undergo fur-
ther endovascular treatment or open surgical repair. The
cause of rupture of aneurysms after endovascular repair
with other devices may be different from the AneuRx
experience and include fabric tears and strut failures.27-30
COMPARISON TO OPEN REPAIR
Endovascular repair compares favorably to open surgi-
cal repair in the short term, with a significant reduction in
morbidity, reduced blood loss, shorter hospital stay, and
earlier return to function.4,7 There was no difference in 1-
year patient survival between patients treated with
endovascular procedures and those treated with open
surgery in the phase II AneuRx clinical trial. In a similar
fashion, concurrent comparison of endoluminal and open
repair of aneurysms revealed no differences in survival
rate.7 Long-term controlled trials comparing open with
endovascular repair have not yet been reported. Although
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some have assumed that patients who have undergone
open surgical repair are no longer at risk of aneurysm rup-
ture once they have recovered from the operation, this has
not proved to be the case. Patients are at risk of pseudo-
aneurysm rupture, suprarenal and iliac aneurysm forma-
tion, graft infection, aortoenteric fistula, and graft
thrombosis after open surgical repair.31-36 The risk of
death from late rupture of abdominal aneurysms and
pseudoaneurysms after elective open surgery was 5% in
three large series of 1126 patients monitored for an aver-
age of 5 years.31,35,36 The long-term late aneurysm-related
death rate after open aneurysm repair including deaths
from ruptured true and false aneurysms, aortoenteric fis-
tula, and graft infections among 1474 patients is 6%
(range 1.5% to 7.5%).31,34-36 Recent reports have demon-
strated that “endoleaks” and ruptures can occur after con-
ventional open aneurysm repair37 just as they can after
endovascular repair. Thus the true differences in long-
term outcome between endovascular and open aneurysm
repair remain to be determined. However, the long-term
risk of aneurysm rupture after endovascular treatment
appears, thus far, to be no higher and perhaps to be lower
than standard open surgical repair.
SUMMARY
The AneuRx stent graft has markedly reduced the mor-
bidity of aortic aneurysm repair and is effective in prevent-
ing aneurysm rupture in the great majority of patients. In
clinical trial follow-up extending to 4 years, the device is
effective in preventing aneurysm rupture in 99.5% of
patients. Most aneurysm ruptures have occurred in patients
in early clinical trials who were treated with a stiff bifurca-
tion stent graft, which is no longer manufactured. Thus the
long-term risk of rupture may be less than that suggested
by early reports. The AneuRx experience suggests that
endograft fixation rather than endoleak is the primary
determinant of long-term results. Therefore all patients
should be monitored with post-treatment imaging studies
to evaluate aneurysm size and stent graft fixation.
The authors acknowledge Rita Jacob for data management,
Rita Wedell for preparation of the manuscript, and Debra Shaver
for preparation of the figures.
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